Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ALDH1A3
REST API REST API
Homo sapiens
ALDH1A3 is differentially expressed in 108 experiments: 81 organism parts: prostate, liver, ... (79 more);, 156 disease states: normal, colorectal adenocarcinoma, ... (154 more);, 36 cell types 132 cell lines 5 compound treatments and 37 other conditions.
Synonyms ALDH6, RALDH3
Orthologs Q9DD46_CHICK (Gallus gallus)   AL1A3_RAT (Rattus norvegicus)   aldh1a3 (Danio rerio)   ALD5 (Saccharomyces cerevisiae)   Aldh1a3 (Mus musculus)   ALD4 (Saccharomyces cerevisiae)   ALD6 (Saccharomyces cerevisiae)   ENSCING00000007939 (Ciona intestinalis)   ALDH1A3 (Bos taurus)   aldh1a3 (Xenopus laevis)   ALDH1A3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term oxidoreductase activity, cytoplasm, metabolic process, aldehyde dehydrogenase [NAD(P)+] activity, positive regulation of apoptosis, response to drug, aldehyde dehydrogenase (NAD) activity, protein homodimerization activity, face development, nucleus accumbens development, pituitary gland development, retinoic acid metabolic process, kidney development, retinal metabolic process, optic cup morphogenesis involved in camera-type eye development, retinoic acid biosynthetic process, thyroid hormone binding, embryonic eye morphogenesis, olfactory pit development, embryonic camera-type eye development, oxidation-reduction process, NAD+ binding
InterPro Term Aldehyde_DH_dom
UniProt Accession B4E0M6, P47895, Q7Z3A2
Search EB-eye ENSG00000184254
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-GEOD-1577, E-MTAB-24, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-18005, E-GEOD-19397, E-GEOD-2450, ... (22 experiments)

Factor Value U/D Experiments
MDA468
2
E-MEXP-440, E-MTAB-62
SW480
2
E-MEXP-1014, E-GEOD-2509
MCF12A
1
E-MTAB-62
u-2os cells
1
E-MTAB-62
caki-1
1
E-MTAB-62
GM00719
1
E-TABM-321
126 more value(s).


Cell type

studied in E-AFMX-5, E-MTAB-24, E-GEOD-19397, E-MTAB-25, E-GEOD-3920, ... (15 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-3204
double positive thymocyte
1
E-GEOD-1460
intrathymic T progenitor cell
1
E-GEOD-1460
adipocyte
1
E-AFMX-5
neurosphere cell
1
E-MEXP-551
whole blood
1
E-MTAB-25
30 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-10797, E-GEOD-2508, E-AFMX-5, E-GEOD-1577, ... (22 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-GEOD-96, E-MTAB-62, E-MEXP-1327
adenocarcinoma
2
E-MEXP-1331, E-MTAB-62
cervical carcinoma
2
E-MEXP-1331, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
obesity
2
E-GEOD-2508, E-MTAB-62
squamous cell carcinoma cell line, 4h after infection with wildtype Streptococcus pyogenes
1
E-MTAB-62
150 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-2292, E-GEOD-5824, E-GEOD-6462, E-GEOD-4006 ... (5 experiments)

Factor Value U/D Experiments
bacterial endotoxin
1
E-GEOD-3284
none
52
1
E-GEOD-5824
17beta-estradiol
1
1
3
E-GEOD-4006, E-GEOD-2292
control
1
1
15
E-GEOD-4006, E-GEOD-3284
epidermal growth factor
2
1
E-GEOD-6462


Biopsy tissue

studied in E-GEOD-5851

Factor Value U/D Experiments
abdomen (soft tissue mass)
1
E-GEOD-5851
liver
1
E-GEOD-5851


BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-21340

Clinical info
studied in E-GEOD-6710, E-MEXP-1251, E-GEOD-2034

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

Developmental stage
studied in E-MTAB-62

Disease staging
studied in E-GEOD-1323, E-GEOD-2509, E-TABM-147

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Genotype
studied in E-GEOD-2152, E-MEXP-1996, E-GEOD-2724, E-GEOD-18005, E-GEOD-2725 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1273

Individual
studied in E-MTAB-197, E-GEOD-3284, E-TABM-125, E-TABM-450, E-MEXP-455, ... (7 experiments)

Infection
studied in E-GEOD-6802, E-GEOD-923

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

organ
studied in E-GEOD-24283

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-923

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922

Tissue
studied in E-GEOD-30573

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Processing time: 0.827 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM